HK1050860A1 - Nordihydroguaiaretic derivatives for use in treatment of tumors - Google Patents

Nordihydroguaiaretic derivatives for use in treatment of tumors

Info

Publication number
HK1050860A1
HK1050860A1 HK03103192A HK03103192A HK1050860A1 HK 1050860 A1 HK1050860 A1 HK 1050860A1 HK 03103192 A HK03103192 A HK 03103192A HK 03103192 A HK03103192 A HK 03103192A HK 1050860 A1 HK1050860 A1 HK 1050860A1
Authority
HK
Hong Kong
Prior art keywords
tumors
treatment
nordihydroguaiaretic
derivatives
methods
Prior art date
Application number
HK03103192A
Other languages
English (en)
Inventor
Ru Chih C Huang
Jonathan D Heller
Jih Ru Hwu
Ke Yung King
Gholam Hosein Hakimelahi
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of HK1050860A1 publication Critical patent/HK1050860A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK03103192A 1999-10-15 2003-05-06 Nordihydroguaiaretic derivatives for use in treatment of tumors HK1050860A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/418,594 US6214874B1 (en) 1999-10-15 1999-10-15 Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
PCT/US2000/028612 WO2001028494A2 (en) 1999-10-15 2000-10-16 Nordihydroguaiaretic derivatives for use in treatment of tumors

Publications (1)

Publication Number Publication Date
HK1050860A1 true HK1050860A1 (en) 2003-07-11

Family

ID=23658774

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103192A HK1050860A1 (en) 1999-10-15 2003-05-06 Nordihydroguaiaretic derivatives for use in treatment of tumors

Country Status (11)

Country Link
US (4) US6214874B1 (de)
EP (1) EP1231914B1 (de)
JP (2) JP4062664B2 (de)
CN (1) CN1309381C (de)
AT (1) ATE350030T1 (de)
AU (1) AU783015C (de)
CA (1) CA2387873C (de)
DE (1) DE60032795T2 (de)
HK (1) HK1050860A1 (de)
SG (1) SG144712A1 (de)
WO (1) WO2001028494A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
WO2004112695A2 (en) * 2003-05-20 2004-12-29 Erimos Pharmaceutical Llc Methods and compositions for delivery of catecholic butanes for treatment of obesity
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
EP1748767B1 (de) 2004-05-28 2011-12-28 Unigen, Inc. 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'-dihydroxyphenyl)-propan als hochwirksamer tyrosinase-inhibitor
WO2006014669A2 (en) * 2004-07-20 2006-02-09 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
CA2583336A1 (en) * 2004-10-06 2006-04-20 Johns Hopkins University Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
EP1848278B1 (de) * 2005-01-27 2016-09-07 Erimos Pharmaceuticals LLC Formulierungen zur oralen verabreichung von catecholischen butanen mit ndga-verbindungen
WO2007101111A2 (en) * 2006-02-23 2007-09-07 Erimos Pharmaceuticals Llc Methods of treating influenza viral infections
ES2476249T3 (es) * 2006-10-02 2014-07-14 Erimos Pharmaceuticals Llc Derivados del NDGA tetrasustituidos por medio de enlaces éter y enlaces carbamatos y sus síntesis y usos farmacéuticos
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
WO2008088806A1 (en) * 2007-01-16 2008-07-24 Johns Hopkins University Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants
HUE029409T2 (en) * 2007-05-11 2017-02-28 Convatec Technologies Inc Osmotic device
BRPI0916188A2 (pt) 2008-07-21 2017-08-29 Unigen Inc Série de composto para clareamento da pele (iluminação)
KR20100011963A (ko) * 2008-07-25 2010-02-03 국립암센터 Ｎｄｇａ를 포함하는 트란스글루타미나제 억제용 조성물
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2010054264A1 (en) * 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
KR101976642B1 (ko) 2011-03-24 2019-05-09 유니젠, 인크. 디아릴프로판의 제조를 위한 화합물 및 방법
US9084779B2 (en) 2011-05-31 2015-07-21 The Johns Hopkins University Conjugates of nitroimidazoles and their use as chemotherapeutic agents
US9456995B2 (en) 2012-07-18 2016-10-04 The Johns Hopkins University Methods for inhibition of BNIP3 and prevention and treatment of ischemia reperfusion injury by tetra-O-methyl nordihydroguaiaretic acid
EP2961412A4 (de) 2013-02-26 2016-11-09 Triact Therapeutics Inc Krebstherapie
CA2923667A1 (en) * 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
MX2017002227A (es) 2017-02-17 2018-08-16 Promotora Tecnica Ind S A De C V Composicion mejorada a base de acido norhidroguayaretico.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276060A (en) 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) * 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4774229A (en) 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
US5559149A (en) * 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5646186A (en) * 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N

Also Published As

Publication number Publication date
CN1391471A (zh) 2003-01-15
DE60032795D1 (de) 2007-02-15
EP1231914B1 (de) 2007-01-03
EP1231914A4 (de) 2004-04-14
CN1309381C (zh) 2007-04-11
US20030065016A1 (en) 2003-04-03
AU783015C (en) 2006-08-24
WO2001028494A3 (en) 2002-01-10
AU783015B2 (en) 2005-09-15
DE60032795T2 (de) 2007-11-08
JP2008019278A (ja) 2008-01-31
JP2003511477A (ja) 2003-03-25
US6417234B1 (en) 2002-07-09
SG144712A1 (en) 2008-08-28
CA2387873C (en) 2008-12-30
WO2001028494A2 (en) 2001-04-26
ATE350030T1 (de) 2007-01-15
US6214874B1 (en) 2001-04-10
CA2387873A1 (en) 2001-04-26
US20050267208A1 (en) 2005-12-01
JP4062664B2 (ja) 2008-03-19
WO2001028494A9 (en) 2002-08-01
EP1231914A2 (de) 2002-08-21
AU1207501A (en) 2001-04-30
US6958411B2 (en) 2005-10-25

Similar Documents

Publication Publication Date Title
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
TR200102711T2 (tr) Kriz halindeki başağrılarının iyileştirilmesinde kullanıma yönelik antikonvülsan türevler
ZA200108413B (en) Use of glycosyceramide synthesis inhibitors in therapy.
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
FR2794744B1 (fr) Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
AU2495200A (en) Compositions and methods for the treatment of tumor
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
PL352330A1 (en) Derivatives of pyridopyranoazepine, making of same and use of same in therapy
MY138883A (en) Use of asiatic acid for treatment of cencer
HK1045986A1 (en) Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders.
HK1030885A1 (en) The use of isatin and oxindole derivatives in the preparation of a medicament for use in the treatment of mycobacterial disease
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
EP1198255A4 (de) Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
JO2199B1 (en) Replaced pyrrols
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
MXPA02004704A (es) Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo.
AU2001291256A1 (en) Methods and compositions for the identification, assessment and therapy of human cancers

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PE Patent expired

Effective date: 20201015